MedTrace Logo

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03266692 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-30

No results posted yet for this study

Summary

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

Conditions

Interventions

BIOLOGICAL

ACTR087

Autologous T cell product

BIOLOGICAL

SEA-BCMA

B-cell maturation antigen (BCMA)-directed antibody

Sponsors & Collaborators

  • Seagen Inc.

    collaborator INDUSTRY

  • Cogent Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Jessica Sachs, MD · Cogent Biosciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-22
Primary Completion
2019-10-01
Completion
2019-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266692 on ClinicalTrials.gov